Technology | March 20, 2007

Cholesterol Testing Brought Directly to Consumers

Cholestech Corp., provider of point-of-care health management solutions for chronic disease, and Life Line Screening, provider of mobile preventive health screenings, have teamed up to bring cholesterol, glucose and c-reactive protein testing directly to consumers across the country. With 85 vans across the U.S. and 1.4 million participants per year, Life Line Screening, the leader in the emerging trend of consumer-accessible screenings for stroke, vascular disease and osteoporosis has selected the Cholestech point-of-care testing system to screen Americans for risk factors‚ LDX associated with stroke, heart disease, diabetes and inflammatory disorders.

The LDX testing system will become part of Life Line Screening’s current preventive health services, which include non-invasive ultrasound screenings for stroke, abdominal aortic aneurysm, peripheral arterial disease and osteoporosis.
In collaboration with Cholestech, Life Line Screening can provide its participants laboratory-accurate results of their complete lipid panel, including total cholesterol, LDL, HDL and triglycerides; blood glucose; and high sensitivity C-reactive protein.

Related Content

Digital Health Devices Used at Point of Care May Improve Diagnostic Certainty
News | Point of Care Testing | August 05, 2019
A West Virginia-based rural medical outreach event showcased the use of point-of-care technology in an ambulatory...
Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing | July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
Alere point of care POC testing for INR
News | Point of Care Testing | July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing | May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
HyperMed Imaging, HyperView portable tissue oxygenation measurement system, FDA clearance
Technology | Point of Care Testing | January 27, 2017
HyperMed Imaging Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing | December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology
INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing | December 07, 2016
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substanti
Siemens, FDA clearance, Xprecia Stride Coagulation Analyzer, point-of-care testing
Technology | Point of Care Testing | November 10, 2016
Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand-held portable...
Abbott, Alere, acquisition, point of care diagnostics
News | Point of Care Testing | February 03, 2016
Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere. Under the terms of the agreement,...
News | Point of Care Testing | December 22, 2015
Trinity Biotech plc announced submission of its Meritas Point of Care Analyzer and Meritas cardiac troponin-I (cTnI)...